FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973061702> ?p ?o ?g. }

• W1973061702 endingPage "105" @default.
• W1973061702 startingPage "99" @default.
• W1973061702 abstract "Migraine is three times as common in females as in males, and attacks may be more severe and difficult to treat in women. However, no study specifically addressed possible gender differences in response to antimigraine therapy. The objective of this study was to review the efficacy of frovatriptan vs. other triptans, in the acute treatment of migraine in subgroups of subjects classified according to gender (men vs. women) through a pooled analysis of three individual randomized Italian studies. 414 patients suffering from migraine with or without aura were randomized to frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). All studies had a multicenter, randomized, double-blind, crossover design. After treating 1-3 episodes of migraine in no more than 3 months with the first treatment, patients switched to the other treatment for the next 3 months. In this analysis, traditional migraine endpoints were compared between the 66 men and 280 women of the intent-to-treat population. At baseline, long-term and debilitating migraine attacks were more frequently reported by women than men. During the observation period, the proportion of pain-free attacks at 2 h did not significantly differ between frovatriptan and the comparators in either men (32 vs. 38 %, p = NS) or women (30 vs. 33 %, p = NS). Pain relief was also similar between treatments for both genders (men: 56 % frovatriptan vs. 57 % comparators; women: 55 vs. 57 %; p = NS for both). The rate of relapse was significantly lower with frovatriptan than with the comparators in men (24 h: 10 vs. 30 %; 48 h: 21 vs. 39 %; p < 0.05) as well as in women (24 h: 14 vs. 23 %; 48 h: 28 vs. 40 %; p < 0.05). The rate of adverse drug reactions was significantly larger with comparators, irrespectively of gender. Although migraine presents in a more severe form in women, frovatriptan seems to retain its good efficacy and favorable sustained antimigraine effect regardless of the gender." @default.
• W1973061702 created "2016-06-24" @default.
• W1973061702 creator A5009318704 @default.
• W1973061702 creator A5011147943 @default.
• W1973061702 creator A5019189552 @default.
• W1973061702 creator A5028267184 @default.
• W1973061702 creator A5034246138 @default.
• W1973061702 creator A5037904746 @default.
• W1973061702 creator A5045732436 @default.
• W1973061702 creator A5057834516 @default.
• W1973061702 creator A5067585857 @default.
• W1973061702 date "2014-05-01" @default.
• W1973061702 modified "2023-10-10" @default.
• W1973061702 title "Gender and triptan efficacy: a pooled analysis of three double-blind, randomized, crossover, multicenter, Italian studies comparing frovatriptan vs. other triptans" @default.
• W1973061702 cites W1494531753 @default.
• W1973061702 cites W1972978693 @default.
• W1973061702 cites W1977898022 @default.
• W1973061702 cites W1989090397 @default.
• W1973061702 cites W1998443917 @default.
• W1973061702 cites W2026593367 @default.
• W1973061702 cites W2034286336 @default.
• W1973061702 cites W2037956209 @default.
• W1973061702 cites W2039942911 @default.
• W1973061702 cites W2043131125 @default.
• W1973061702 cites W2045425896 @default.
• W1973061702 cites W2048085523 @default.
• W1973061702 cites W2055895292 @default.
• W1973061702 cites W2068126822 @default.
• W1973061702 cites W2078794100 @default.
• W1973061702 cites W2088423580 @default.
• W1973061702 cites W2092658012 @default.
• W1973061702 cites W2125350651 @default.
• W1973061702 cites W2126844100 @default.
• W1973061702 cites W2142961788 @default.
• W1973061702 cites W2151495151 @default.
• W1973061702 cites W2158846562 @default.
• W1973061702 cites W2161470374 @default.
• W1973061702 cites W2166530830 @default.
• W1973061702 cites W4229899347 @default.
• W1973061702 cites W4246461511 @default.
• W1973061702 cites W4256440121 @default.
• W1973061702 doi "https://doi.org/10.1007/s10072-014-1750-4" @default.
• W1973061702 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4035544" @default.
• W1973061702 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24867845" @default.
• W1973061702 hasPublicationYear "2014" @default.
• W1973061702 type Work @default.
• W1973061702 sameAs 1973061702 @default.
• W1973061702 citedByCount "18" @default.
• W1973061702 countsByYear W19730617022015 @default.
• W1973061702 countsByYear W19730617022016 @default.
• W1973061702 countsByYear W19730617022017 @default.
• W1973061702 countsByYear W19730617022018 @default.
• W1973061702 countsByYear W19730617022019 @default.
• W1973061702 countsByYear W19730617022020 @default.
• W1973061702 countsByYear W19730617022021 @default.
• W1973061702 countsByYear W19730617022022 @default.
• W1973061702 countsByYear W19730617022023 @default.
• W1973061702 crossrefType "journal-article" @default.
• W1973061702 hasAuthorship W1973061702A5009318704 @default.
• W1973061702 hasAuthorship W1973061702A5011147943 @default.
• W1973061702 hasAuthorship W1973061702A5019189552 @default.
• W1973061702 hasAuthorship W1973061702A5028267184 @default.
• W1973061702 hasAuthorship W1973061702A5034246138 @default.
• W1973061702 hasAuthorship W1973061702A5037904746 @default.
• W1973061702 hasAuthorship W1973061702A5045732436 @default.
• W1973061702 hasAuthorship W1973061702A5057834516 @default.
• W1973061702 hasAuthorship W1973061702A5067585857 @default.
• W1973061702 hasBestOaLocation W19730617021 @default.
• W1973061702 hasConcept C126322002 @default.
• W1973061702 hasConcept C142724271 @default.
• W1973061702 hasConcept C168563851 @default.
• W1973061702 hasConcept C170493617 @default.
• W1973061702 hasConcept C204787440 @default.
• W1973061702 hasConcept C27081682 @default.
• W1973061702 hasConcept C2776497919 @default.
• W1973061702 hasConcept C2777030092 @default.
• W1973061702 hasConcept C2777119127 @default.
• W1973061702 hasConcept C2777350023 @default.
• W1973061702 hasConcept C2778541695 @default.
• W1973061702 hasConcept C2778871607 @default.
• W1973061702 hasConcept C2778938600 @default.
• W1973061702 hasConcept C2779085531 @default.
• W1973061702 hasConcept C2908647359 @default.
• W1973061702 hasConcept C42219234 @default.
• W1973061702 hasConcept C71924100 @default.
• W1973061702 hasConcept C87813604 @default.
• W1973061702 hasConcept C99454951 @default.
• W1973061702 hasConceptScore W1973061702C126322002 @default.
• W1973061702 hasConceptScore W1973061702C142724271 @default.
• W1973061702 hasConceptScore W1973061702C168563851 @default.
• W1973061702 hasConceptScore W1973061702C170493617 @default.
• W1973061702 hasConceptScore W1973061702C204787440 @default.
• W1973061702 hasConceptScore W1973061702C27081682 @default.
• W1973061702 hasConceptScore W1973061702C2776497919 @default.
• W1973061702 hasConceptScore W1973061702C2777030092 @default.
• W1973061702 hasConceptScore W1973061702C2777119127 @default.
• W1973061702 hasConceptScore W1973061702C2777350023 @default.
• W1973061702 hasConceptScore W1973061702C2778541695 @default.

• next